We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Syagen Technology Signs Cross Licensing Agreement with Applied Biosystems/MDS SCIEX
News

Syagen Technology Signs Cross Licensing Agreement with Applied Biosystems/MDS SCIEX

Syagen Technology Signs Cross Licensing Agreement with Applied Biosystems/MDS SCIEX
News

Syagen Technology Signs Cross Licensing Agreement with Applied Biosystems/MDS SCIEX

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Syagen Technology Signs Cross Licensing Agreement with Applied Biosystems/MDS SCIEX"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Syagen Technology, Inc. announced that it has signed a cross licensing agreement with the joint venture of Applied Biosystems/MDS SCIEX, both analytical instrumentation businesses, to share patent claims covering atmospheric pressure photo-ionization (APPI) and methods of usage.

Syagen will supply the PhotoMate® APPI source to the majority of the liquid chromatorgraphy/mass spectrometry (LC/MS) instrument manufacturers and Applied Biosystems/MDS SCIEX will supply the Photospray® APPI source to customers of its LC/MS product line.

APPI is an important complement to electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI). It expands the range and classes of compounds that can be analyzed with LC/MS instruments, including nonpolar molecules, not easily ionized by either ESI or APCI, and by exhibiting less ion suppression than the other types of ionization sources.

“We are very excited by this cross licensing agreement with Applied Biosystems/MDS SCIEX The terms will allow our respective customers greater flexibility in maximizing the benefits of APPI,” says Dr. Jack A. Syage, CEO of Syagen.

Advertisement